The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 43 | The surgeons evolving role in clinical trials & collaboration w/ oncologists in melanoma treatment
Andrew Furness, MD, PhD, Royal Marsden Hospital, London, UK, discusses the evolving role of surgeons in clinical trials, emphasizing that they will gain more autonomy and collaboration opportunities with medical oncologists, particularly in the context of neoadjuvant immune checkpoint inhibition and TIL therapy. He highlights the need for surgeons to adapt their approaches based on research findings to optimize outcomes. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
